Generate Biomedicines
Founded Year
2018Stage
Unattributed VC | AliveTotal Raised
$708MRevenue
$0000Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-6 points in the past 30 days
About Generate Biomedicines
Generate Biomedicines operates as a therapeutics company focused on generative biology within the biomedicine sector. The company uses machine learning and biological engineering to create medicines, including antibodies, peptides, and enzymes, with specific therapeutic functions. Generate Biomedicines serves the pharmaceutical and biotechnology industries with its drug discovery platform. It was founded in 2018 and is based in Somerville, Massachusetts.
Loading...
ESPs containing Generate Biomedicines
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The AI-derived biological drugs market leverages AI and machine learning to discover and develop novel biologic therapeutics, including proteins, nucleic acids, cell therapies, and their combinations. These companies combine AI algorithms with experimental validation to engineer complex biological structures, optimize therapeutic properties, and enhance manufacturing processes for heat-sensitive a…
Generate Biomedicines named as Highflier among 15 other companies, including AbCellera, AbSci, and BigHat Biosciences.
Generate Biomedicines's Products & Differentiators
The Generate Platform
Against the backdrop of a healthcare industry marked by high costs, long timelines, and a staggering 90% failure rate for new therapeutics, The Generate Platform is revolutionizing drug discovery and development using Generative AI. Trained on both proprietary experimental data and the comprehensive compendium of known protein structures and sequences, the platform unlocks the ability to design entirely new protein-therapeutics (which represent 70% of all pharmaceuticals) faster and more effectively than traditional trial-and-error processes. In doing so, we’re writing a new playbook for how drug discovery and development is done, reducing the time and cost it takes to bring medicines to patients while maintaining patient safety.
Loading...
Research containing Generate Biomedicines
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Generate Biomedicines in 8 CB Insights research briefs, most recently on Sep 19, 2025.
Sep 19, 2025 report
Book of Scouting Reports: AI Drug Discovery
Aug 22, 2025 report
Book of Scouting Reports: Generative AI in Healthcare & Life Sciences
May 23, 2025
The AI in drug R&D market map
Feb 27, 2024
The generative AI boom in 6 charts
Oct 25, 2023 report
State of Digital Health Q3’23 Report
Aug 29, 2023
The pharma AI market mapExpert Collections containing Generate Biomedicines
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Generate Biomedicines is included in 7 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,309 items
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AI 100 (All Winners 2018-2025)
100 items
Generative AI
2,951 items
Companies working on generative AI applications and infrastructure.
Artificial Intelligence (AI)
20,894 items
Generate Biomedicines Patents
Generate Biomedicines has filed 5 patents.
The 3 most popular patent topics include:
- animal viral diseases
- betacoronaviruses
- animal virology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/5/2023 | 5/28/2024 | Betacoronaviruses, Clusters of differentiation, Immunology, Animal viral diseases, Viral respiratory tract infections | Grant |
Application Date | 5/5/2023 |
|---|---|
Grant Date | 5/28/2024 |
Title | |
Related Topics | Betacoronaviruses, Clusters of differentiation, Immunology, Animal viral diseases, Viral respiratory tract infections |
Status | Grant |
Latest Generate Biomedicines News
Nov 4, 2025
The global AI in biotechnology market was valued at USD 3.23 billion in 2024, and is expected to reach USD 14.97 billion by 2033, rising at a CAGR of 21.1% during the forecast period. This new 2025 market report presents an in-depth assessment of the global AI in biotechnology market dynamics, opportunities, future road map, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook in the global AI in biotechnology market. The report also provides up-to-date historical market size data for the period 2022 - 2024 and an illustrative forecast to 2033 covering key market aspects like market value, share, analysis, and trends for the global AI in biotechnology market. The integration of artificial intelligence (AI) within the biotechnology sector is transforming how companies approach research and development. By leveraging advanced data analytics and machine learning algorithms, biotechnology firms can enhance their capabilities, optimize processes, and ultimately improve outcomes. Such technology is not merely a trend but a significant evolution in the industry. The report provides a detailed analysis of the current industry situation and market requirements, highlighting facts about the market size, market share, revenue for global AI in biotechnology market segments, and a vivid forecast to 2033. It also provides a comprehensive analysis of the pricing landscape, policies and regulation, and reimbursement pattern by countries and region. The report also offers analysis and information according to categories such as market segments, product offering, end-user, function, deployment, geographies, companies and competitive landscape. The report also provides a detailed description of the porter's five forces analysis, SWOT analysis, funding, merger and acquisitions, pipeline, growth drivers and challenges of the global AI in biotechnology market. An in-depth analysis of the main competitors in the industry has been conducted to offer insights into their business profiles, services, primary strategies, contracts, alliances, agreements, new service introductions, mergers and acquisitions, and recent events related to the AI in biotechnology market. This report covers the competitive analysis of new startups in the AI in biotechnology market ecosystem. Additionally, the research also addresses industry-specific trends like technology assessment, ecosystem and market analysis, as well as the patent and regulatory environment, among others. AI in Biotechnology Market Growth Drivers Several factors are driving the growth of AI in the biotechnology market. First, the increasing volume of biological data necessitates advanced analytical tools. Traditional methods are often insufficient to process and interpret large datasets, highlighting the essential role of AI. Furthermore, AI-driven technologies enable faster drug discovery and personalized medicine, streamlining the path from laboratory to market. Looking ahead, the synergy of AI and biotechnology is poised to unlock new discoveries and efficiency gains, solidifying its importance in the healthcare landscape. Key Features of the Report The global AI in biotechnology market provides granular level information about the market size, market share, historic market (2020 - 2024), and forecast (2025 - 2033). Annualized revenues and country level analysis for each market segment. Analysis of business strategies by identifying the key market segments positioned for strong growth in the future. The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and key strategies. The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market. The report tracks recent innovations, key developments, and start-up details that are actively working in the market. The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios. The report analyses the impact of the socio-political environment through SWOT analysis and competition through porter's five force analysis. Through study of the key business strategies and recommendations on future market approach. Comprehensive analysis of the competitive structure of the market. Demand side and supply side analysis of the market Key Players in the Global AI in Biotechnology Market Absci Corporation Antiverse AstraZeneca Cradle Bio DeepMind (Alphabet) Exscientia GenBio AI Generate Biomedicines Insilico Medicine Merck Novartis Owkin Pfizer Recursion Pharmaceuticals Roche Key Attributes: Report Attribute Details No. of Pages Forecast Period Estimated Market Value (USD) in 2025 $3.23 Billion Forecasted Market Value (USD) by 2033 $14.97 Billion Compound Annual Growth Rate Regions Covered Global Key Topics Covered: 1. Market Definition 2. Research and Methodology 3. Executive Summary 4. Global AI in Biotechnology Market - Market Dynamics 4.1 Growth Drivers 4.2 Challengers 4.3 Funding and Mergers & Acquisitions 5. Global AI in Biotechnology Market - Industry Analysis 5.1 SWOT Analysis 5.2 Porter's Analysis 6. Global AI in Biotechnology Market & Forecast (2022 - 2033) 7. Global AI in Biotechnology Market Share & Forecast (2022 - 2033) 7.1 By Offering 7.2 By Function 7.3 By Deployment Mode 7.4 By End User 7.5 By Region 7.6 By Country 8. By Offering - Global AI in Biotechnology Market & Forecast (2022 - 2033) 8.1 End-to-End Solutions 8.2 Niche Solutions 8.3 Technologies 8.4 Services 9. By End Use - Global AI in Biotechnology Market & Forecast (2022 - 2033) 9.1 Pharmaceutical Companies 9.2 Biotechnology Companies 9.3 Research Institutes & Labs 9.4 Healthcare Providers 9.5 Clinical Research Organizations 10. By Function - Global AI in Biotechnology Market & Forecast (2022 - 2033) 10.1 Research & Development 10.2 Regulatory Compliance 10.3 Manufacturing & Supply Chain 10.4 Launch & Commercial 10.5 Post Marketing Surveillance & Patient Support 10.6 Corporate 11. By Deployment Mode - Global AI in Biotechnology Market & Forecast (2022 - 2033) 11.1 Cloud-based Solutions 11.2 On-premise Solutions 12. By Region - AI in Biotechnology Market & Forecast (2022 - 2033) 12.1 North America 12.2 Europe 12.3 Asia Pacific 12.4 Latin America 12.5 Middle East & Africa 13. By Country - Global AI in Biotechnology Market & Forecast (2022 - 2033) (102 page) 13.1 United States 13.1.1 Market Size 13.1.2 Growth Drivers 13.1.3 Regulatory Policy & Reimbursements 13.2 Canada 13.3 Germany 13.4 United Kingdom 13.5 France 13.6 Italy 13.7 Spain 13.8 Switzerland 13.9 Netherlands 13.10 China 13.11 Japan 13.12 India 13.13 South Korea 13.14 Israel 13.15 Rest of the Countries (ROC) 13.15.1 Market Size 13.15.2 Growth Drivers 14. Global AI in Biotechnology Market - Key Players Profile 14.1 Business Overview 14.2 Recent Developments 14.3 SWOT Analysis 14.4 Market Strategy For more information about this report visit https://www.researchandmarkets.com/r/oy5155 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on businesswire.com: https://www.businesswire.com/news/home/20251104641468/en/ Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Generate Biomedicines Frequently Asked Questions (FAQ)
When was Generate Biomedicines founded?
Generate Biomedicines was founded in 2018.
Where is Generate Biomedicines's headquarters?
Generate Biomedicines's headquarters is located at 101 South Street, Somerville.
What is Generate Biomedicines's latest funding round?
Generate Biomedicines's latest funding round is Unattributed VC.
How much did Generate Biomedicines raise?
Generate Biomedicines raised a total of $708M.
Who are the investors of Generate Biomedicines?
Investors of Generate Biomedicines include Alumni Ventures, Samsung Ventures, Novartis, ARCH Venture Partners, Alaska Permanent Fund and 17 more.
Who are Generate Biomedicines's competitors?
Competitors of Generate Biomedicines include Antiverse and 7 more.
What products does Generate Biomedicines offer?
Generate Biomedicines's products include The Generate Platform.
Who are Generate Biomedicines's customers?
Customers of Generate Biomedicines include Amgen and Novartis.
Loading...
Compare Generate Biomedicines to Competitors
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions, and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
Insitro is a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology. The company has a machine learning platform that combines in vitro cellular data with human clinical data to identify insights and interventions in metabolism, oncology, and neuroscience. Insitro's approach uses technology to model disease states and design therapeutic interventions. It was founded in 2018 and is based in South San Francisco, California.
DiaCarta specializes in precision diagnostics within the healthcare sector, providing diagnostic products and services related to cancer patient management. The company offers tools for early detection, diagnosis, therapy selection, and monitoring of cancer progression, along with tests for infectious diseases. DiaCarta's technologies, XNA and isobDNA, aim to improve genetic alteration detection in the precision diagnostic field. It was founded in 2012 and is based in Pleasanton, California.
Fractal provides artificial intelligence (AI) solutions across various sectors, focusing on AI, engineering, and design. The company offers services including business intelligence, sustainability initiatives, revenue growth management, and conversational AI for sales and customer service. Fractal's solutions aim to support AI across organizations and assist in decision-making processes. It was founded in 2000 and is based in Maharashtra, India.
TernaryTx specializes in the discovery of molecular glues within the biotechnology sector. It offers a computational design platform that leverages machine learning and molecular simulations to assist in drug discovery. It primarily serves the immunology sector. It was founded in 2024 and is based in London, United Kingdom.
Anima Biotech works in the field of drug discovery within the biotech sector. The company provides a platform that integrates mRNA biology with artificial intelligence (AI) imaging technologies to visualize and analyze the life cycle of mRNA in cells, with the goal of understanding disease mechanisms and identifying drug targets. Anima Biotech's solutions are utilized in the pharmaceutical industry for drug discovery and development. It was founded in 2014 and is based in Bernardsville, New Jersey.
Loading...